These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26996311)

  • 21. Differences in the knowledge and compliance with secondary prevention of stroke between transient ischaemic attack patients with and without subsequent stroke.
    Zhao J; Zhou M; Guo J; Zhang J; Yang Y; Yu F; He L
    J Clin Nurs; 2014 Oct; 23(19-20):2939-48. PubMed ID: 24444395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry.
    Hwong WY; Abdul Aziz Z; Sidek NN; Bots ML; Selvarajah S; Kappelle LJ; Sivasampu S; Vaartjes I
    BMC Neurol; 2017 Nov; 17(1):203. PubMed ID: 29169331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Educational level and risk profile and risk control in patients with coronary heart disease.
    Bruthans J; Mayer O; De Bacquer D; De Smedt D; Reiner Z; Kotseva K; Cífková R;
    Eur J Prev Cardiol; 2016 May; 23(8):881-90. PubMed ID: 26283652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Greater Adherence to Secondary Prevention Medications Improves Survival After Stroke or Transient Ischemic Attack: A Linked Registry Study.
    Dalli LL; Kim J; Cadilhac DA; Greenland M; Sanfilippo FM; Andrew NE; Thrift AG; Grimley R; Lindley RI; Sundararajan V; Crompton DE; Lannin NA; Anderson CS; Whiley L; Kilkenny MF
    Stroke; 2021 Nov; 52(11):3569-3577. PubMed ID: 34315251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk factors and mortality in patients with coronary heart disease.
    Prugger C; Wellmann J; Heidrich J; Brand-Herrmann SM; Keil U
    Eur J Epidemiol; 2008; 23(11):731-7. PubMed ID: 18855105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
    McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
    Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
    Kotseva K; Wood D; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Amouyel P; Bruthans J; Castro Conde A; Cífková R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pajak A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D;
    Eur J Prev Cardiol; 2016 Apr; 23(6):636-48. PubMed ID: 25687109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognosis at six months for coronary patients: impact of antiplatelet agents and statins].
    Ferrières J; Cambou JP; Cantet C; Guize L
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S10-6. PubMed ID: 16411646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperlipidemia is associated with lower risk of poststroke mortality independent of statin use: A population-based study.
    Yeramaneni S; Kleindorfer DO; Sucharew H; Alwell K; Moomaw CJ; Flaherty ML; Woo D; Adeoye O; Ferioli S; de Los Rios La Rosa F; Martini S; Mackey J; Khatri P; Kissela BM; Khoury JC
    Int J Stroke; 2017 Feb; 12(2):152-160. PubMed ID: 27649737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prescription at discharge improves long-term adherence for secondary stroke prevention.
    Tsai JP; Rochon PA; Raptis S; Bronskill SE; Bell CM; Saposnik G
    J Stroke Cerebrovasc Dis; 2014 Oct; 23(9):2308-15. PubMed ID: 25149205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of 10-year coronary heart disease risk in Caribbean type 2 diabetic patients using the UKPDS risk engine.
    Ezenwaka CE; Nwagbara E; Seales D; Okali F; Hussaini S; Raja B; Jones-LeCointe A; Sell H; Avci H; Eckel J
    Int J Cardiol; 2009 Mar; 132(3):348-53. PubMed ID: 18191239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lifestyle behaviour and risk factor control in coronary patients: Belgian results from the cross-sectional EUROASPIRE surveys.
    De Smedt D; De Sutter J; De Pauw M; Vandekerckhove H; Trouerbach J; De Backer G; Willems AM; Pardaens S; Vervaet P; Deweerdt N; De Bacquer D
    Acta Cardiol; 2019 Feb; 74(1):21-27. PubMed ID: 29458303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Secondary prevention of ischemic non cardioembolic stroke].
    Armario P; Pinto X; Soler C; Cardona P
    Clin Investig Arterioscler; 2015; 27(6):287-300. PubMed ID: 25771074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy?
    Johnson P; Rosewell M; James MA
    Cerebrovasc Dis; 2007; 23(2-3):156-61. PubMed ID: 17124397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect.
    Rudnicka AR; Ashby D; Brennan P; Meade T
    Arch Intern Med; 2003 Jun; 163(12):1454-60. PubMed ID: 12824095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disparities in Secondary Prevention between Stroke and Coronary Heart Disease in China: Cross-Sectional Community-Based Study, 2014-2016.
    Xia S; Wang C; Du X; Guo L; Du J; Zheng Y; Wu S; Guang X; Zhou X; Lin H; Cheng X; Anderson CS; Huffman MD; Dong J; Yuan Y; Ma C
    Cerebrovasc Dis; 2022; 51(3):384-393. PubMed ID: 34879381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Health care quality: medication and prevention in patients with and without coronary heart disease].
    Baberg HT; Yazar A; Brechmann T; Grewe P; Kugler J; De Zeeuw J; Bojara W; Lawo T; Mügge A
    Med Klin (Munich); 2004 Jan; 99(1):1-6. PubMed ID: 14716479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.